tance of neuroendocrine activation in heart failure and the possibility of modifying such mechanisms of the disease process have greatly improved treatment in clinical practice. 4 Thus, angiotensin-converting enzyme (ACE) inhibitors have been established as standard therapy for patients with chronic heart failure due to left ventricular systolic dysfunction, with proven effects on mortality and symptoms related to worsening heart failure. 4, 5 Despite the benefits of this mode of therapy, mortality and morbidity remain high for patients with heart failure.
The role of ␤-blocker treatment in the management of chronic heart failure has taken time to clarify. The results from meta-analyses of previous smaller studies of various ␤-blockers in heart failure, including the carvedilol studies, have indicated beneficial effects. [6] [7] [8] Two studies onthesurvivaleffectsof␤ 1 -blockadepublished in 1999, the Cardiac Insufficiency Bisoprolol Study (CIBIS) II 9 and the present Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure(MERIT-HF), 10 demonstratedthat total mortality was reduced by 34%.
Although the survival benefit of ␤ 1 -blockade in chronic heart failure due to systolic dysfunction has been established, the need for hospital care, safety aspects, symptom alleviation, and improved quality of life are additional important aspects of treatment, for both the patient and the clinician. However, the impact of ␤-blockers on these outcomes has not been fully explored. Accordingly, the MERIT-HF was designed to study the effects of controlled-release/extendedrelease metoprolol succinate (metoprolol CR/XL) on mortality, as previously reported, 10 as well as hospitalizations, symptoms, and quality of life.
METHODS

Organization
The MERIT-HF was a randomized, double-blind placebo-controlled trial with a single-blind, 2-week placebo run-in period. Randomization was performed according to an optimal allocation procedure, which balanced the metoprolol CR/XL and placebo groups for investigational site, age, sex, race/ ethnicity, cause of heart failure, previous acute myocardial infarction (AMI), and, within the previous AMI group, time since last AMI, diabetes mellitus, ejection fraction, and New York Heart Association (NYHA) functional class. An interactive voice recording system (Covance, Princeton, NJ) was used to provide investigators with the computergenerated study drug number based on the optimal allocation procedure.
A total of 3991 patients with symptomatic chronic heart failure and decreased ejection fraction who were stabilized with standard treatment were randomized (FIGURE 1) at 313 investigational sites in the United States and 13 European countries (Belgium, Czech Republic, Denmark, Finland, Germany, Hungary, Iceland, the Netherlands, Norway, Poland, Sweden, Switzerland, and the United Kingdom). The study was approved by the institutional review board of each hospital and all patients provided written informed consent.
The Independent Endpoint Committee, whose 5 members were unaware of treatment status, classified all events from copies of medical charts and other documents according to prespecified definitions. An Independent Safety Committee monitored safety issues during the study.
The stopping rule for efficacy was based on the total number of expected deaths, analyzedbasedontheintent-to-treatprinciple. The study used an asymmetrical group sequential procedure to monitor total mortality. A Peto-type boundary 11 was used for monitoring a positive trend. This approach favors a large critical Z-value for all interim tests before the end of the trial. The cumulative ␣ level was planned to be .0012, .0024, and .0036 at the first, second, and third interim analysestotakeplacewhen25%,50%,and75%, respectively, of the total number of expected deaths had occurred. The cumulative probability of early stopping for harm was planned to be .005, .010, and .015 at the first, second, and third interim analyses, respectively.
Outcome Measures
There were 2 primary outcome measures: totalmortalityandthecombinedendpoint of total mortality or all-cause hospitalization (time to first event). The MERIT-HF was stopped early, on October 31, 1998, because the second preplanned interim analysis showed a significant 34% reduction in total mortality in the metoprolol CR/XL group. 10 As previously reported, 145 patients died in the metoprolol CR/ XL group compared with 217 in the placebo group.
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The following combined end points (time to first event) were also predefined: total mortality or hospitalization due to worsening heart failure; death or heart transplantation; cardiac death or nonfatal AMI; and total mortality or hospitalization due to worsening heart failure or emergency department visit due to worsening heart failure. Other end points were number of hospitalizations due to heart failure and other cardiovascular causes, withdrawal of study drug due to worsening heart failure, and change in NYHA functional class. Effect on quality of life was assessed in a substudy that was conducted in the United States, United Kingdom, Sweden, Norway, and the Netherlands.
Patients
The major inclusion criteria were symptomatic heart failure for at least 3 months, Resting heart rate had to be 68/min or more. Patients had to be receiving optimal treatment (defined as any combination of diuretics and an ACE inhibitor) for at least 2 weeks prior to randomization. If an ACE inhibitor was not tolerated, hydralazine, long-acting nitrate, or an angiotensin II blocker could be used. Digitalis also could be prescribed. In addition, the inclusion criteria included a stable clinical condition during the 2-week placebo run-in phase before randomization (TABLE 1) .
The main exclusion criteria included AMI or unstable angina pectoris within 28 days before randomization, indication or contraindication for treatment with ␤ 1 -blockade, severe decompensated heart failure (eg, pulmonary edema, hypoperfusion), or supine systolic blood pressure of less than 100 mm Hg. A more detailed description of the study protocol has been published previously.
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Treatment and Measurements
At the randomization visit, patients were allocated to treatment with metoprolol CR/XL or placebo administered once daily. The starting dosage was one 25-mg tablet once per day (half of a 25-mg tablet was recommended for patients with NYHA functional class III or IV). It was recommended to double the dosage after each 2-week period to reach the target dosage level of 200 mg/d of metoprolol CR/XL or placebo. This regimen could be modified according to the judgment of the investigator. If a patient did not tolerate increased titration of study drug, temporary reduction in dosage or increase in diuretic dosage was advocated. During follow-up, patient visits were scheduled every third month.
At each visit, the investigators judged and documented the patient's NYHA functional class. The Minnesota Living with Heart Failure questionnaire was completed by patients at randomization, after each 6-month treatment period, and atstudyclosure. 13 Thisquestionnaireconsists of 21 items; the total score ranges from 0 to 105, with lower scores indicating better quality of life. The McMaster Overall Treatment Evaluation questionnaire (OTE) was completed by the patients after each 6-month treatment period and at study closure.
14 This questionnaire has 3 items that assess the overall effect according to whether a patient experienced any change in activity limitation,symptoms,orfeelingssincethetreatment started, using 7-point scales. Any improvement or deterioration was subsequently scored by the patient in terms of magnitude and importance to the patient's ability to carry out daily activities.
Hospitalizations were defined as care at an acute-care hospital lasting for 24 hours or more and had to be separated from other hospitalizations by separate dates for discharge and admission. Transfer from one ward to a different type of hospital ward was counted as 1 hospitalization. Hospitalization due to heart failure was defined as documentation in the medical charts indicating worsening heart failure as the reason for hospitalization. If competing reasons were judged to be of equal importance, the heart failure diagnosis took preference. Emergency department visit was defined as care in an urgent fashion with urgent-care treatment such as intravenous medication.
Statistical Analyses
The power calculation showed that the mean follow-up time had to be 2.4 years if 1600 patients were randomized to each treatmentgroupover14months.Thiswas based on a significance level of ␣ = .04 (2-sided) for the first primary end point of total mortality and ␣ = .01 for the second primaryendpointoftotalmortalityorany hospitalization (time to first event), a power of at least 80% (␤Յ.2), and the following assumptions: a 9.4% mean annual mortality in the placebo group, a mean risk-reducing effect of metoprolol CR/XL of30%(withtreatment),andawithdrawal rate from study drug of 20% the first year and 5% annually thereafter. 12 Because patient recruitment proceeded faster than planned, 3991 patients were randomized duringtherecruitmentperiod,therebyincreasing the power of the study.
The analysis was by intent to treat. The main analyses used the log-rank test for the comparison of the 2 randomized groups and the Cox proportional hazards model to calculate relative risk and 95% confidence intervals (CIs). Additional Cox proportional hazards regression analyses of the combined end points of total mortality or all-cause hospitalizations (time to first event) and total mortality or hospitalizations due to heart failure (time to first event) were performed to explore any unfavorable outcome in prespecified risk groups, defined by entry characteristics as previously described.
10,12 For ejection fraction, systolic and diastolic blood pressure, and heart rate, patients in the lowest tertile were compared with those in the middle and upper tertiles. Regarding age, the upper tertile was compared with the middle and lower tertiles. New York Heart Association class, etiology of heart failure, smok- ing status, sex, previous AMI, diabetes mellitus, and hypertension were also prespecified as risk groups. Ischemic and nonischemic heart disease have been defined as the 2 major causes of heart failure. Hypertension was defined as pharmacologically treated high blood pressure, and diabetes mellitus was defined as a clinical diagnosis made by the investigator. More than 180 events in any such subgroup would yield a power of at least 70% to detect a 30% increase in risk. Data on complementary subgroups having less than 180 events have also been depicted. The sample size calculation for the quality of life substudy showed that with 419 patients in each group, it would be possible to detect a difference of 3 units on total Living with Heart Failure score between the treatment groups based on the following assumptions: SD for change = 16, ␣ = .05, and ␤ = .20. A net difference of 3 units was judged to be a clinically meaningful change. The changes in NYHA class and OTE score were tested by means of a permutation test using raw data scores. Changes in Living with Heart Failure score were analyzed using an analysis of covariance model with adjustment for the baseline Living with Heart Failure score. A 2-sided PϽ.05 was regarded as statistically significant.
RESULTS
Randomization began on February 14, 1997, and the last patient was randomized on April 14, 1998. The International Steering Committee stopped the study on October 31, 1998, on recommendation from the Independent Safety Committee. The second preplanned interim analysis (at the halfway point) had shown that the predefined criterion for termination of the study was met and exceeded. In total, 2004 patient-years were accumulated in the metoprolol CR/XL group and 1977 in the placebo group (total mortality). The corresponding patientyears for the combined end point of total mortality or all-cause hospitalization were 1650 vs 1600 patient-years, and for total mortality or hospitalization for worsening heart failure were 1880 vs 1840 patient-years, respectively. The mean follow-up time was 1 year.
The 2 groups were similar at entry (Table 1) . Furosemide daily dosage at baseline and during follow-up was 66 mg/d and 70 mg/d in the metoprolol CR/XL group and 65 mg/d and 73 mg/d in the placebo group, respectively. The ACE inhibitor daily dosage was also similar at baseline and during follow-up in both randomization groups. For enalapril, it was 14 mg/d at baseline and 15 mg/d at follow-up in both groups; corresponding dosages at baseline and follow-up, respectively, for cap- The patients who participated in the quality of life substudy (n = 741) had characteristics similar to those of the entire group (mean age, 64.4 years; female sex, 28%; NYHA class II, 39%; NYHA class III, 56%; NYHA class IV, 5%; mean ejection fraction, 0.27; previous AMI, 51%; and treatment with ACE inhibitor or angiotensin II blocker, 96%).
Combined End Points
Metoprolol CR/XL significantly reduced all combined end points (time to first event) compared with placebo (TABLE 2, FIGURE 2, and FIGURE 3). Total mortality or all-cause hospitalizations (the prespecified second primary end point) was reduced by 19% (Figure 2) , total mortality or hospitalization for worsening heart failure by 31% (Figure 3) , death or heart transplantation by 32%, cardiac death or nonfatal AMI by 39% (Figure 3) , and total mortality or hospitalization due to worsening heart failure or emergency department visit due to worsening heart failure by 32%. No significant increase in total mortality or all-cause hospitalizations (time to first event) or in total mortality orhospitalizationsduetoworseningheart failure (time to first event) were observed in any of the predefined subgroups analyzed for safety reasons (FIGURE 4).
Hospitalizations
Compared with placebo, metoprolol CR/ XL reduced the number of patients with any hospitalization, the total number of hospitalizations, and the total number of days in the hospital due to all causes (FIGURE 5, TABLE 3 ). This was mainly explained by a reduction in the number of patients who were hospitalized for worsening heart failure, accompanied by decreases in the total number of hospitalizations and total number of days in the hospital due to heart failure (Table 3, Figure 5 ). To account for the improved survival with metoprolol CR/XL, the proportion of days spent alive outside the hospital was also calculated as 95% in the metoprolol CR/XL group and 93% in the placebo group (PϽ.001).
Physician and Patient Assessment of Treatment Effects
Physicians classified NYHA functional class at baseline and at the last visit in 009; FIGURE 6 ). In the metoprolol CR/XL group, 185 patients (50%) reported improvement, and patients' evaluations of the importance of this change were available for 184 patients, showing that 132 patients (72%) judged this improvement as important, very important, or extremely important to carry out daily activities. In the placebo group, 148 patients (40%) reported improvement that was judged to be important, very important, or extremely important by 72% of these patients.
Living with Heart Failure forms completed at randomization and at the last visit were available for 670 patients. Scores were similar at randomization in the 2 study groups. The total Living with Heart Failure score, adjusted for the score at baseline, decreased (improved) by 0.7 in the metoprolol CR/XL group (n = 331)and increased (deteriorated) by 0.2 in the placebo group (n = 339) (mean difference, -0.9; 95% CI, -3.4 to 1.6; P = .20).
Withdrawal of Study Drug
The most frequent adverse events necessitating withdrawal of study drug were worsening heart failure, atrial fibrillation, and angina pectoris, and these events were less frequent in the metoprolol CR/XL group than in the placebo group (TABLE 4) . Dizziness, bradycardia, and hypotension occurred slightly more frequently in the metoprolol CR/XL group.
Permanent withdrawal of study drug due to any cause during the study is shown in Figure 2 and occurred in 279 patients in the metoprolol CR/XL group and 310 patients in the placebo group (risk reduction for withdrawal decreased by 10% in the metoprolol CR/XL group; 95% CI, −5% to 24%; P = .18). Permanent withdrawal of study drug due to any adverse event occurred in 196 patients in the metoprolol CR/XL group and 234 patients in the placebo group (risk reduction, 17%; 95% CI, −1% to 31%; P = .06). Worsening heart failure was the main reason for withdrawal in 64 patients (3.2%) in the metoprolol CR/XL group and 85 (4.2%) in the placebo group (risk reduction, 25%; 95% CI, −4% to 46%; P = .08).
COMMENT
This study demonstrated that metoprolol CR/XL, a ␤ 1 -blocker given once per day in addition to conventional therapy to patients with chronic heart failure, improved survival as previously reported, 10 reduced the need for hospital admissions due to worsening heart failure, and improved symptoms and well-being.
In the MERIT-HF, there were no differences between the study groups in underlying pharmacological treatment for heart failure at baseline or during followup. All-cause mortality or hospitalizations (the prespecified second primary end point, time to first event) was significantly reduced by 19% in the metoprolol CR/XL group. Correspondingly, total deaths or hospitalizations due to worsening heart failure were reduced by 31%. The annual mortality in the placebo group was 11.2% and total mortality was reduced by 34% in the metoprolol CR/XL group. 10 Despite this improved survival and more patients at risk for hospital admissions, fewer patients were hospitalized due to any cause in the metoprolol CR/XL group, mainly due to a 35% reduction in the number of patients hospitalized for worsening heart failure. The total number of days in the hospital due to heart failure was reduced to a similar degree in the metoprolol CR/XL group, with no increase in hospitalizations for other reasons. Conversely, the number of days alive without need for hospital care was higher in the metoprolol CR/XL group than in the placebo group. Given the comparatively low cost of ␤-blocker therapy and the high cost of hospitalizations, the 36% reduction in days spent in the hospital for worsening heart failure suggests a positive effect on health care costs with metoprolol CR/XL treatment in patients with chronic heart failure. It is noteworthy that there was considerable comorbidity among these patients because hospitalizations due to noncardiovascular causes accounted for 30% of all days spent in the hospital and one quarter of all days was due to cardiovascular causes other than worsening heart failure ( Table 3 , placebo group).
Our results are consistent with data from the CIBIS-II study, in which treatment with the ␤ 1 -blocker bisoprolol also reduced hospital admissions due to any cause and due to worsening heart failure. 9 The smaller carvedilol studies also have shown reductions in hospitalizations. 7, 8 The mechanisms involved in the beneficial effects of ␤ 1 -blockade in patients with chronic heart failure are not completely known. However, it is well established that in patients with chronic heart failure due to systolic dysfunction of various etiologies, metoprolol has favorable effects on left ventricular geometry and function, myocardial energy balance, and exercise capacity. [15] [16] [17] In patients with dilated cardiomyopathy, metoprolol has been found to reduce heart transplantations and to improve NYHA functional class and quality of life. 17, 18 In line with these previous observations, the MERIT-HF results showed that symptoms of heart failure improved according to judgments made by the responsible physicians, as did quality of life as assessed by patients on the OTE. Improvement in quality of life was of considerable importance for a large proportion of patients. The observation that the OTE but not the Living with Heart Failure questionnaire showed significant improvement in quality of life may reflect the different constructions of these 2 instruments. The former is a global assessment of treatment effects on activity limitation, symptoms, and feelings, whereas the latter is a 21-item questionnaire used at baseline and during follow-up (see "Methods" section). Given the decrease in hospitalizations and the improvement in both NYHA class and in OTE score, the sensitivity of the Living with Heart Failure questionnaire to assess beneficial changes in quality of life might be questionable. A recent study showed that retrospective measures, such as the 7-point scale used in the OTE, may be more sensitive to change than serial measures and also correlate more strongly with patient's' satisfaction with change. 19 The previously published documentation of the effect of ␤-blockade on the Living with Heart Failure score in patients with heart failure relates mainly to nonselective ␤-blockade with carvedilol therapy, showing no statistically significant effect. [20] [21] [22] Metoprolol CR/XL was well tolerated. Withdrawal of study drug from all causes was 10% lower 10 and withdrawal due to worsening heart failure was 25% lower in the metoprolol CR/XL group compared with the placebo group. These findings are of interest, especially against the background that no metoprolol CR/XL test dose had been given prior to initiating double-blind treatment. For the most frequent adverse reactions leading to withdrawal of study drug, including worsening heart failure, atrial fibrillation, and angina pectoris, withdrawal was more common in the placebo group. Fewer than 1 of 100 patients treated for 1 year *CR/XL indicates controlled release/extended release. Adverse events that led to withdrawal of study drug are specified if the frequency of the cause-specific adverse event was greater than 0.5% in either group. The net difference (metoprolol CR/XL − placebo) refers to the percentage of patients treated during the first year of treatment (1836 vs 1819 patient-years of follow-up until withdrawal of study medicine or death in the metoprolol CR/XL group and placebo group, respectively). †Patients may have had more than 1 reason for withdrawal. ‡The cumulative net difference for bradycardia, dizziness, and hypotension in the metoprolol CR/XL group was 0.9%. §The total number of patients who had a myocardial infarction during follow-up was 35 vs 41 in the metoprolol CR/XL and placebo groups, respectively.
withdrew from metoprolol CR/XL treatment because of bradycardia, dizziness, or hypotension. There were no specific safety concerns observed in any of the preidentified risk groups. In this study, controlled-release/ extended-release metoprolol succinate, once per day, was used. This formulation leads to a more pronounced and even ␤-blockade over 24 hours compared with conventional immediate-release metoprolol tartrate tablets, 50 mg 3 times per day. 23 In patients with chronic heart failure, the dosing schedule can be simplified with metoprolol CR/XL and the target dosage also can be increased to 200 mg once per day compared with 50 mg 3 times per day with the conventional formulation, without increasing the peak plasma concentration of the drug. 24 The titration schedule started with a low oncedaily dosage, 25 mg/d for those in NYHA class II and 12.5 mg/d for those in NYHA class III or IV, with increased titration every 2 weeks. The target dosage, 200 mg/d, was reached by 64% of the patients, and 87% received 100 mg/d or more.
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The mean dosage was 159 mg/d. 10 The combined results from MERIT-HF and CIBIS II demonstrate that it is safe to treat patients with heart failure with ␤ 1 -blockers by using a low starting dosage and gradual increased titration.
This study has several limitations. Several categories of patients were not included (eg, patients with severe heart failure who were confined to bed, patients with heart failure and an ejection fraction of more than 0.40, and patients with heart failure early after AMI). The group of patients in NYHA functional class IV was small, resulting in wide 95% CIs overlapping those in NYHA functional classes II and III. 10 However, results from a recent meta-analysis of several studies indicate thattreatmentwith␤-blockersconferssignificant beneficial effects on the clinical outcome in patients in NYHA class IV. 25 In conclusion, the MERIT-HF study demonstrates that treatment with metoprolol CR/XL once daily added to standard therapy for patients with mild to severe heart failure due to left ventricular systolic dysfunction improves survival, reduces the need for hospital admissions due to worsening heart failure, improves symptoms of heart failure, and increases well-being.
